SOUTH SAN FRANCISCO, Calif., May 1 /PRNewswire-FirstCall/ -- Renovis, Inc. (NASDAQ:RNVS) announced today that its stockholders approved the adoption of the merger agreement with Evotec AG...
SOUTH SAN FRANCISCO, Calif., April 25 /PRNewswire-FirstCall/ -- Renovis, Inc. (NASDAQ:RNVS), today announced that PROXY Governance, Inc. and Egan-Jones Proxy Services have joined ISS/Risk...
SOUTH SAN FRANCISCO, April 22 /PRNewswire-FirstCall/ -- Renovis, Inc. (NASDAQ:RNVS), today announced that Glass Lewis & Co., a leading proxy advisory firm, has joined ISS/Risk Metrics in...
SOUTH SAN FRANCISCO, Calif., April 18 /PRNewswire-FirstCall/ -- Renovis, Inc. (NASDAQ:RNVS), today announced that Institutional Shareholder Services (ISS), one of the nation's leading proxy...
SOUTH SAN FRANCISCO, Calif., April 3, 2008 /PRNewswire-FirstCall/ -- Renovis, Inc. (NASDAQ:RNVS), a biopharmaceutical company focused on the discovery and development of drugs for major medical...
SOUTH SAN FRANCISCO, Calif., March 14 /PRNewswire-FirstCall/ -- Renovis, Inc. (NASDAQ:RNVS), a biopharmaceutical company focused on the discovery and development of drugs for major medical needs...
SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Renovis, Inc. (NASDAQ:RNVS), a biopharmaceutical company focused on the discovery and development of drugs for major medical needs...
SOUTH SAN FRANCISCO, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Renovis, Inc. (NASDAQ:RNVS) announced today Executive Chairman John Walker will present an overview of the company at the CIBC 18th...
CEO Corey Goodman Steps Down; John Walker, Board Chair, Named Executive Chairman SOUTH SAN FRANCISCO, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Renovis, Inc. (NASDAQ:RNVS), a biopharmaceutical...
SOUTH SAN FRANCISCO, Calif., Aug. 7 /PRNewswire-FirstCall/ -- Renovis, Inc. (NASDAQ:RNVS), a biopharmaceutical company focused on the discovery and development of drugs for major medical needs...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.